CN109313192B - 核小体-转录因子复合体用于癌症检测的用途 - Google Patents

核小体-转录因子复合体用于癌症检测的用途 Download PDF

Info

Publication number
CN109313192B
CN109313192B CN201780031827.0A CN201780031827A CN109313192B CN 109313192 B CN109313192 B CN 109313192B CN 201780031827 A CN201780031827 A CN 201780031827A CN 109313192 B CN109313192 B CN 109313192B
Authority
CN
China
Prior art keywords
cancer
tissue
subject
transcription factor
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780031827.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109313192A (zh
Inventor
J.V.米卡莱夫
J.赖斯-菲尔霍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belgian Volition SPRL
Original Assignee
Belgian Volition SPRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55968658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109313192(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Belgian Volition SPRL filed Critical Belgian Volition SPRL
Publication of CN109313192A publication Critical patent/CN109313192A/zh
Application granted granted Critical
Publication of CN109313192B publication Critical patent/CN109313192B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780031827.0A 2016-03-22 2017-03-22 核小体-转录因子复合体用于癌症检测的用途 Expired - Fee Related CN109313192B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1604806.8 2016-03-22
GBGB1604806.8A GB201604806D0 (en) 2016-03-22 2016-03-22 Method of identifying a cancer of unknown origin
PCT/EP2017/056851 WO2017162755A1 (en) 2016-03-22 2017-03-22 Use of nucleosome-transcription factor complexes for cancer detection

Publications (2)

Publication Number Publication Date
CN109313192A CN109313192A (zh) 2019-02-05
CN109313192B true CN109313192B (zh) 2022-07-26

Family

ID=55968658

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780031827.0A Expired - Fee Related CN109313192B (zh) 2016-03-22 2017-03-22 核小体-转录因子复合体用于癌症检测的用途

Country Status (12)

Country Link
US (1) US20200363418A1 (https=)
EP (3) EP3433616B2 (https=)
JP (1) JP6777757B2 (https=)
KR (2) KR102246699B1 (https=)
CN (1) CN109313192B (https=)
AU (1) AU2017238442A1 (https=)
CA (1) CA3018428C (https=)
ES (2) ES2861440T5 (https=)
GB (1) GB201604806D0 (https=)
MY (1) MY187655A (https=)
SG (1) SG11201807991QA (https=)
WO (1) WO2017162755A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202242130A (zh) * 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
US20240318259A1 (en) * 2021-09-24 2024-09-26 Oncocross Co., Ltd. Method for determining primary tumor site
WO2025073909A1 (en) 2023-10-04 2025-04-10 Belgian Volition Srl Pcr method for detecting ctcf occupied cfdna fragments

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102472753A (zh) * 2009-07-02 2012-05-23 欧洲分子生物学实验室 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法
CN102498219A (zh) * 2009-06-15 2012-06-13 癌症学术基金会 在得自对象的生物学样品中评价癌症的方法
CN104053993A (zh) * 2011-09-01 2014-09-17 新加坡意志私人有限公司 用于检测含组蛋白变体的核小体的方法
CN104067125A (zh) * 2011-12-07 2014-09-24 新加坡意志私人有限公司 用于检测核小体加合物的方法
CN104067124A (zh) * 2011-09-01 2014-09-24 新加坡意志私人有限公司 用于检测含核苷酸的核小体的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249548A1 (en) * 2000-03-27 2001-10-08 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells
ES2399110T3 (es) * 2001-09-14 2013-03-25 F. Hoffmann-La Roche Ag Diagnóstico diferencial de los trastornos del metabolismo del hierro por medio de cuatro parámetros independientes y recomendaciones para el tratamiento de estos trastornos del metabolismo del hierro
US7248921B2 (en) * 2003-06-02 2007-07-24 Cameron Health, Inc. Method and devices for performing cardiac waveform appraisal
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040236188A1 (en) * 2003-05-19 2004-11-25 Ge Medical Systems Information Method and apparatus for monitoring using a mathematical model
US8029989B2 (en) * 2005-08-26 2011-10-04 The Trustees Of The University Of Pennsylvania Method using snail transcriptional repressor
US20090298097A1 (en) * 2007-07-17 2009-12-03 Harris Pamela J Methods for the diagnosis of lung cancer
JP4873510B2 (ja) * 2008-07-01 2012-02-08 学校法人日本大学 標的遺伝子特異的ヒストン修飾制御剤
GB201303576D0 (en) 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102498219A (zh) * 2009-06-15 2012-06-13 癌症学术基金会 在得自对象的生物学样品中评价癌症的方法
CN102472753A (zh) * 2009-07-02 2012-05-23 欧洲分子生物学实验室 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法
CN104053993A (zh) * 2011-09-01 2014-09-17 新加坡意志私人有限公司 用于检测含组蛋白变体的核小体的方法
CN104067124A (zh) * 2011-09-01 2014-09-24 新加坡意志私人有限公司 用于检测含核苷酸的核小体的方法
CN104067125A (zh) * 2011-12-07 2014-09-24 新加坡意志私人有限公司 用于检测核小体加合物的方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin;Matthew W.Snyder;《Cell》;20160114;第164卷(第1-2期);第57-68页 *
Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy;Christin Wittwer;《International Journal of Cancer》;20130809;第133卷(第11期);第2619-2630页 *
Epigenetic Control of Gene Expression in the Lung;Ivana V.Yang;《Am J Respir Crit Care Med》;20110515;第183卷(第10期);第1295-1301页 *
GATA3-dependent cellular reprogramming requires activation-domain dependent recruitment of a chromatin remodeler;Motoki Takaku;《Genome Biology》;20160227;第17卷(第1期);第1-16页 *
Nucleosome-Driven Transcription Factor Binding and Gene Regulation;Cecilia Ballare´;《Molecular Cell》;20121121;第49卷(第1期);第67-79页 *
The Expression Levels of Transcription Factors T-bet, GATA-3, RORγt and FOXP3 in Peripheral Blood Lymphocyte (PBL) of Patients with Liver Cancer and their Significance;Ze-Wei Lin;《International Journal of Medical Sciences》;20150101;第12卷(第1期);第7-16页 *

Also Published As

Publication number Publication date
ES2861440T3 (es) 2021-10-06
EP4270007A3 (en) 2023-12-20
KR102369544B1 (ko) 2022-03-03
WO2017162755A1 (en) 2017-09-28
EP3839513B1 (en) 2023-06-14
EP3433616B2 (en) 2024-07-24
KR102246699B1 (ko) 2021-05-04
EP3433616A1 (en) 2019-01-30
KR20190013707A (ko) 2019-02-11
KR20210049954A (ko) 2021-05-06
US20200363418A1 (en) 2020-11-19
AU2017238442A1 (en) 2018-10-11
GB201604806D0 (en) 2016-05-04
CA3018428C (en) 2024-03-19
EP4270007A2 (en) 2023-11-01
SG11201807991QA (en) 2018-10-30
EP3433616B1 (en) 2020-12-30
JP2019510974A (ja) 2019-04-18
CA3018428A1 (en) 2017-09-28
EP3839513A1 (en) 2021-06-23
EP3839513C0 (en) 2023-06-14
ES2951136T3 (es) 2023-10-18
JP6777757B2 (ja) 2020-10-28
MY187655A (en) 2021-10-07
ES2861440T5 (en) 2025-02-05
CN109313192A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
JP6263474B2 (ja) ヌクレオソームアダクト検出法
CN109313192B (zh) 核小体-转录因子复合体用于癌症检测的用途
KR20110076829A (ko) 암 진단 마커로서의 보체 ｃ９
US20160003848A1 (en) Method for predicting therapy efficacy using nucleosome structure biomarkers
KR20110076830A (ko) 소세포폐암 및 비소세포폐암 진단 마커로서의 보체 ｃ９
TWI757285B (zh) 癌症偵測方法
HK40055426A (en) Use of dna-transcription factor complexes for cancer detection
US20250044291A1 (en) Method for the detection of blood cancer
HK40003771B (en) Use of nucleosome-transcription factor complexes for cancer detection
HK1249176B (en) Method for detecting nucleosome adducts

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220726

CF01 Termination of patent right due to non-payment of annual fee